Tags

Type your tag names separated by a space and hit enter

Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients.
Hemoglobin 2011; 35(1):13-21H

Abstract

To assess the Hb F response to hydroxyurea (HU) in Yemeni sickle cell disease, 86 patients attending hospitals in Sana'a City, Yemen, were studied. Group I (short-term follow-up, n = 21) were treated with 500 mg/day HU for 3-6 months; group II (long-term, n = 26) were treated with 500 mg/day HU for 8-48 months; group III were untreated (n = 39). Hb F levels were monitored using cation exchange high performance liquid chromatography (HPLC). Group I showed significant increase in Hb F level after treatment (10.0 ± 5.8 to 13.8 ± 5.9%). Hb F level increased significantly with treatment in group II when compared to group III. The increase in Hb F level was associated with increased hemoglobin (Hb) levels. Hydroxyurea, even at a low dose, appears to be effective in raising Hb F levels in Yemeni sickle cell disease patients without any association of major side effects. Further study is required to investigate its maximum tolerated dose and its effects on increase in Hb F, frequency of acute crisis and any long-term toxicity.

Authors+Show Affiliations

Department of Hematology, Faculty of Medicine and Health Sciences, Sana'a University, Sana'a, Yemen. hafizalnood@yahoo.co.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21250877

Citation

Al-Nood, Hafiz A., et al. "Fetal Hemoglobin Response to Hydroxyurea in Yemeni Sickle Cell Disease Patients." Hemoglobin, vol. 35, no. 1, 2011, pp. 13-21.
Al-Nood HA, Al-Khawlani MM, Al-Akwa A. Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin. 2011;35(1):13-21.
Al-Nood, H. A., Al-Khawlani, M. M., & Al-Akwa, A. (2011). Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. Hemoglobin, 35(1), pp. 13-21. doi:10.3109/03630269.2011.551748.
Al-Nood HA, Al-Khawlani MM, Al-Akwa A. Fetal Hemoglobin Response to Hydroxyurea in Yemeni Sickle Cell Disease Patients. Hemoglobin. 2011;35(1):13-21. PubMed PMID: 21250877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fetal hemoglobin response to hydroxyurea in Yemeni sickle cell disease patients. AU - Al-Nood,Hafiz A, AU - Al-Khawlani,Mona M, AU - Al-Akwa,Ahmed, PY - 2011/1/22/entrez PY - 2011/1/22/pubmed PY - 2011/6/30/medline SP - 13 EP - 21 JF - Hemoglobin JO - Hemoglobin VL - 35 IS - 1 N2 - To assess the Hb F response to hydroxyurea (HU) in Yemeni sickle cell disease, 86 patients attending hospitals in Sana'a City, Yemen, were studied. Group I (short-term follow-up, n = 21) were treated with 500 mg/day HU for 3-6 months; group II (long-term, n = 26) were treated with 500 mg/day HU for 8-48 months; group III were untreated (n = 39). Hb F levels were monitored using cation exchange high performance liquid chromatography (HPLC). Group I showed significant increase in Hb F level after treatment (10.0 ± 5.8 to 13.8 ± 5.9%). Hb F level increased significantly with treatment in group II when compared to group III. The increase in Hb F level was associated with increased hemoglobin (Hb) levels. Hydroxyurea, even at a low dose, appears to be effective in raising Hb F levels in Yemeni sickle cell disease patients without any association of major side effects. Further study is required to investigate its maximum tolerated dose and its effects on increase in Hb F, frequency of acute crisis and any long-term toxicity. SN - 1532-432X UR - https://www.unboundmedicine.com/medline/citation/21250877/Fetal_hemoglobin_response_to_hydroxyurea_in_Yemeni_sickle_cell_disease_patients_ L2 - http://www.tandfonline.com/doi/full/10.3109/03630269.2011.551748 DB - PRIME DP - Unbound Medicine ER -